Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line
2001 ◽
Vol 13
(12)
◽
pp. 887-894
◽
2012 ◽
Vol 5
(1)
◽
pp. 1-7
◽
2020 ◽
Vol 29
◽
pp. 101602
◽
Keyword(s):